切换导航
About Us
Our Story
Our Mission
History
Global Footprint
Leadership
Board of Directors
Science & Technology
Pipeline
Collaborations
CDMO Services
About CDMO
Strength
Services Offered
Learn More
Investors & Media
Join Us
EN
中文
Home
>
Investors & Media
Investors & Media
Immorna has successfully closed 3 rounds of financing with a total of 8 investors, including leading venture capitals and industry investors.
We welcome new investors. For investment
opportunities, please contact
ir@immornabio.com
News Flow
News Update
Immorna’s mRNA Quadrivalent Seasonal Influenza Vaccine Obtains US. FDA IND Clearance
US. Eastern Time, July 27 2023, Immorna Biotherapeutics, Inc ("Immorna") announces that i...
View More
2023.07
News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company f...
View More
2023.05
News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology compan...
View More
2023.01
News Update
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
MORRISVILLE, N.C., November 21st, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology co...
View More
2022.11
News Update
First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Replicating RNA encoding human IL-12, in Patients with Malignant Solid Tumors
Immorna Announces First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Repl...
View More
2022.11
Immorna Receives IND Clearance to Conduct FIH Study of JCXH-211, the First-in-Class Self-replicating mRNA
Encoding Human IL-12 Protein, in Cancer PatientsRALEIGH, N.C., March 28, 2022 /PRNewswire/ -- Immor...
View More
2022.03
More